HR+/HER2- Breast Cancer (DBCOND0148150)

Identifiers

Synonyms

HR Positive, HER2/Neu Negative Breast Cancer / HR-positive, HER2-negative Breast Cancer / Hormone Receptor-positive/Her2 Negative Breast Cancer / HR+HER2- Breast Cancer / HR + HER2 - breast cancer / HR+ HER2 Negative Breast Cancer / Hormone Receptor Positive, HER2 Negative Breast Cancer / Hormone Receptor Positive (HR+), HER2-negative Breast Cancer / HR+/HER2-negative Breast Cancer / Hormone Receptor Positive，HER2-negative Breast Cancer / Hormone Receptor Positive HER2 Negative Breast Cancer / Hormone Receptor Positive / HER2-negative Breast Cancer / Breast Cancer (HR+HER2-) / Hormone Receptor-positive/HER2-negative Breast Cancer / Hormone Receptor Positive HER-2 Negative Breast Cancer / HR+ HER2- breast cancer / HR+ HER2 Breast Cancer / HR+/HER2-breast Cancer

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05546268	Study of Oral MRT-2359 in Selected Cancer Patients	MRT-2359 Olive oil	treatment	1 / 2	recruiting
NCT05579366	PRO1184 for Advanced Solid Tumors	No drug interventions	treatment	1 / 2	recruiting
NCT06639672	Neoadjuvant Chemotherapy + PD-1 Inhibitor+Different Radiotherapy Fractionations for HR+/HER2- Breast Cancer	No drug interventions	treatment	2	not_yet_recruiting
NCT06404463	QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer	Albumin human Cyclophosphamide Doxorubicin Epirubicin Paclitaxel QL1706	treatment	2	not_yet_recruiting
NCT06343948	A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer	Capecitabine Eribulin Gemcitabine Vinorelbine	treatment	3	recruiting
NCT03394027	ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma	Dordaviprone	treatment	2	completed
NCT04443348	Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)	Capecitabine Carboplatin Cyclophosphamide Doxorubicin Paclitaxel Pembrolizumab	treatment	2	recruiting
NCT03560856	A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer	Fulvestrant Palbociclib	treatment	2	unknown_status
NCT05455619	Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Women With a PI3K Alteration and HR+/Her2- Breast Cancer	Evexomostat	treatment	1 / 2	recruiting
NCT05809024	Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy	Letrozole	treatment	4	recruiting
NCT05159518	A Study of PRT2527 in Participants With Advanced Solid Tumors	No drug interventions	treatment	1	completed
NCT04802876	Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors	Spartalizumab Tislelizumab	treatment	2	recruiting
NCT02791334	A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors	Abemaciclib Merestinib Ramucirumab	treatment	1	active_not_recruiting
NCT05234606	A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors	Pembrolizumab	treatment	1 / 2	withdrawn
NCT06120283	BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors	Fulvestrant Letrozole	treatment	1	recruiting
NCT06201234	Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer	No drug interventions	treatment	2	recruiting
NCT06257264	A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors	Fulvestrant	treatment	1	recruiting
NCT06369285	A Study of Alisertib in Combination with Endocrine Therapy in Patients with HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer	Alisertib	treatment	2	recruiting
NCT05878314	Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer	No drug interventions	Not Available	Not Available	recruiting
NCT02692755	Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer	Fulvestrant Letrozole Palbociclib	treatment	2 / 3	completed
NCT05901428	TCb vs EC-T in High Risk ER+/HER2- Breast Cancer	Carboplatin Cyclophosphamide Docetaxel Epirubicin	treatment	3	recruiting
NCT05608252	VS-6766+Abema+Fulv in Met HR+/HER- BC	Abemaciclib Avutometinib Fulvestrant	treatment	1 / 2	recruiting
NCT05573126	Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer	No drug interventions	treatment	1 / 2	recruiting
NCT03613220	CompLEEment-1 Canadian Correlative Sub-Study	Letrozole Ribociclib	other	2	completed
NCT06611813	Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)	Toripalimab	treatment	2	recruiting
NCT06599216	Adebrelimab Combined with Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer	Adebrelimab	treatment	2	not_yet_recruiting
NCT06470633	To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer	Adebrelimab Cyclophosphamide Docetaxel Epirubicin	treatment	2	not_yet_recruiting
NCT02983045	A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors	Bempegaldesleukin Carboplatin Cisplatin Ipilimumab Nivolumab Paclitaxel Pemetrexed	treatment	1 / 2	completed
NCT05633914	Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer	Paclitaxel Tucidinostat	treatment	2	recruiting
NCT06447623	Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer	Fulvestrant Rivoceranib	treatment	3	recruiting
NCT05789771	Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.	Abemaciclib	Not Available	Not Available	completed
NCT04282031	A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer	Fulvestrant Letrozole	treatment	1 / 2	recruiting
NCT05889871	A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer	Rivoceranib	treatment	3	not_yet_recruiting